Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Revenue (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Revenue data on record, last reported at $191.8 million in Q3 2025.

  • For Q3 2025, Revenue changed 0.33% year-over-year to $191.8 million; the TTM value through Dec 2025 reached $185.6 million, down 74.65%, while the annual FY2024 figure was $732.0 million, 13.59% up from the prior year.
  • Revenue reached $191.8 million in Q3 2025 per AMPH's latest filing, up from -$6.3 million in the prior quarter.
  • Across five years, Revenue topped out at $191.8 million in Q3 2025 and bottomed at -$6.3 million in Q1 2025.
  • Average Revenue over 5 years is $138.8 million, with a median of $137.5 million recorded in 2022.
  • Peak YoY movement for Revenue: soared 50.3% in 2023, then plummeted 103.66% in 2025.
  • A 5-year view of Revenue shows it stood at $120.9 million in 2021, then rose by 11.69% to $135.0 million in 2022, then soared by 31.91% to $178.1 million in 2023, then increased by 4.73% to $186.5 million in 2024, then increased by 2.85% to $191.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $191.8 million in Q3 2025, -$6.3 million in Q1 2025, and $186.5 million in Q4 2024.